GLP-1 Usage to surge with MHRA pill approvals?

In February I wrote that the oral GLP-1 pill would reach the UK in 2026. On Wednesday the MHRA approved it.

I'm not posting this for the I-told-you-so. I'm posting it because most of the industry is reading the wrong headline.

The story everyone's running: a weight-loss pill, easier than injections, bigger market. True, and boring.

The story that actually matters if you make or sell protein: the needle was the last real brake on adoption. Take it away and household penetration doesn't climb, it jumps. We were already at 4.1% of GB households on these medications with injections. A pill removes the single biggest point of friction left.

Now follow that downstream, because this is where it gets uncomfortable.

Every new GLP-1 user is a high-protein, nutrient-dense, portion-controlled shopper. We can already see it in the basket: fat-free yoghurt volumes up 12.9% in twelve weeks, an extra 4.3 million kilograms. That demand was already straining a protein supply chain running at record whey prices. The pill pours petrol on it.

So here's the squeeze nobody's pricing in. Demand for protein-rich formats accelerates, at exactly the moment whey is up 140% in two years and forward contracts are scarce. The brands without secured supply don't just face a cost problem. They face a cost problem during a demand surge they can't fulfil.

This is why fibre stops being the boring bit. Satiety, gut, texture, claims, at a fraction of the cost-per-gram of protein, and not tied to a commodity in crisis. The smart formulation teams aren't fibre-curious any more. They're fibre-maxing, because it's the one lever that answers both the GLP-1 demand and the protein-cost trap at the same time.

The prediction was the easy part. The positioning question is the one that pays: if your roadmap assumes cheap, available protein and a fibre afterthought, this week just told you to rewrite it.

We mapped this chain in February, the pill, the demand surge, the supply squeeze, the fibre answer, in our seventy-8 intelligence. If you want the full read on what the pill does to protein demand and where the margin moves next, message me.